Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8820673 | Revue des Maladies Respiratoires Actualités | 2017 | 10 Pages |
Abstract
Finally, this article describes new perspectives: clinicians expect a lot from the analysis of genotypic alterations in SCLC. A few steps have been made and a new target is already known: DLL3 (Delta Like Protein 3), which is NOTCH ligand. If anti-angiogenic therapies' influence is too weak to go on trying in this direction, immunotherapies, using modern immuno-oncologic treatment, are still giving some hope. But let's remain careful because these therapies are still on development and studies are going on.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
J.-L. Pujol, B. Roch,